Outcomes of a trial of Dexamethasone for Chronic Subdural Hematoma has been published in the New England Journal of Medicine, on behalf of the British Neurosurgical Trainee Research Collaborative and Dex-CSDH Trial Collaborators.
Dex-CSDH is a pragmatic, multi-centre, double-blind, phase III randomised, placebo-controlled trial assessing the clinical utility of a tapering 2-week course of dexamethasone following Chronic Subdural Haematoma. The patients were assigned in a 1:1 ratio to receive a 2-week tapering course of oral dexamethasone, starting at 8 mg twice daily, or placebo. The decision to surgically evacuate the hematoma was made by the treating clinician. The primary outcome was a score of 0 to 3, representing a favorable outcome, on the modified Rankin scale at 6 months after randomization; scores range from 0 (no symptoms) to 6 (death).
The results of the trial suggest that among adults with symptomatic chronic subdural hematoma, most of whom had undergone surgery to remove their hematomas during the index admission, treatment with dexamethasone resulted in fewer favorable outcomes and more adverse events than placebo at 6 months, but fewer repeat operations were performed in the dexamethasone group. Dexamethasone was associated with more adverse events than placebo.
For more information visit: N Engl J Med
Published December 31 2020
A senior Addenbrooke’s early phase trials researcher has praised patients, staff and sponsors who backed a landmark trial which could be a “game changer” in…
Treating newly-diagnosed patients with advanced therapy leads to dramatic improvements in outcomes.
An artificial pancreas developed with the help of staff and patients at Addenbrooke's Hospital is one of four new devices to be rolled out by…